Overview

A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants

Status:
Completed

Trial end date:
2024-05-13

Target enrollment:

Participant gender:

Summary

This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF) compared to placebo using a concentration-QTcF analysis, and with moxifloxacin as positive control, in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Moxifloxacin